Bolla M, Neven A, Maingon P, et al. - This study was sought to present the long-term results in intermediate-risk patients treated with 74 or 78 Gy external-beam radiotherapy (EBRT), as per current guidelines. A total of 819 patients were included in this study. Individuals were assigned randomly between EBRT or EBRT plus AS started on day 1 of EBRT, 481 entered with intermediate-risk (International Union Against Cancer TNM 1997 cT1b-c or T2a with prostate-specific antigen (PSA) ≥ 10 ng/mL or Gleason ≤ 7 and PSA ≤ 20 ng/mL, N0M0) and had EBRT planned at 74 (342 patients, 71.1%) or 78 Gy (139 patients, 28.9%). The results indicated that six months of concomitant and adjuvant AS statistically significantly improves EFS and disease-free survival in intermediate-risk prostatic carcinoma, treated by irradiation at 74 or 78 Gy. As per the findings, the effects on OS and distant metastasis-free survival did not reach statistical significance.